Categories AlphaGraphs, Earnings, Health Care
Infographic: Key financials of Biogen (BIIB) Q2 2020 earnings report
Biogen (NASDAQ: BIIB) reported a 12% increase in adjusted EPS and 2% growth in revenue for the second quarter of 2020. Adjusted EPS of $10.26 and revenue of $3.68 billion in the quarter were better than analysts’ estimates. Shares of Biogen rose about 3% in the pre-market trading session.
While Biogen lifted its EPS guidance for fiscal 2020, it lowered the revenue expectations.
The company lifted FY20 GAAP EPS outlook to a range of $32.00 and $34.00 from the prior guidance range of $29.50 to $31.50. Non-GAAP EPS is now expected to be between $34.00 and $36.00 versus a prior range of $31.50 to $33.50.
Revenue outlook for FY20 is cut down to a range of $13.8 billion to $14.2 billion from the prior expected range of $14.0 billion to $14.3 billion.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
